Company intelligence / Profile preview

Bitterroot Drug

Palo Alto, California, United States

Ownership: Private
Development stage: Other

Overview

Bitterroot Bio is developing BRB-002, a monoclonal antibody therapy targeting the "don't eat me" CD47 pathway for atherosclerosis and other cardiovascular indications. IND-enabling studies show promising efficacy/safety in animal models; clinical trials anticipated within a year. $145M Series A funds Phase 1 and likely Phase 2a trials

Therapeutic areas: Cardiovascular
Modalities: Monoclonal antibodyProtein
Industry: Biotech

Partnerships

ARCH Venture PartnersDeerfield ManagementGV (Google Ventures)Koch Disruptive TechnologiesAlexandria Venture Investments

Beyond the preview

Go deeper on Bitterroot Drug.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bitterroot Drug.

Explore the full profile